Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Golimumab»

Golimumab


Golimumab

Pronunciation: (goe-LIM-ue-mab)Class: Monoclonal antibody

Trade Names:Simponi- Injection, solution 50 mg per 0.5 mL

Pharmacology

Binds to both soluble and transmembrane bioactive forms of human tumor necrosis factor–alpha (TNF-alpha), preventing the binding of TNF-alpha to its receptors, thereby inhibiting the biological activity of TNF-alpha.

Pharmacokinetics

Absorption

Following subcutaneous injection, T max ranges from 2 to 6 days. C max is approximately 2.5 mcg/mL. Absolute bioavailability is approximately 53%.

Distribution

Distributed primarily in the circulatory system with limited extravascular distribution.

Elimination

Mean terminal half-life is approximately 2 wk.

Special Populations

Renal Function Impairment

No studies have been conducted.

Hepatic Function Impairment

No studies have been conducted.

Elderly

No differences were observed based on age.

Gender

No dosage adjustment is needed based on gender.

Race

No differences in pharmacokinetics have been observed based on race.

Indications and Usage

Treatment of moderate to severe active rheumatoid arthritis in combination with methotrexate; treatment of active psoriatic arthritis as monotherapy or in combination with methotrexate; treatment of active ankylosing spondylitis.

Contraindications

Standard considerations.

Dosage and Administration

Adults

Subcutaneous 50 mg once per month.

General Advice

  • Prior to injection, allow the prefilled syringe or auto-injector to sit at room temperature for 30 minutes.
  • Discard any leftover product remaining in the prefilled syringe or prefilled auto-injector.
  • Do not inject into areas where the skin is tender, bruised, red, or hard.
  • Injection sites should be rotated.
  • Do not shake.

Storage/Stability

Store refrigerated at 36° to 46°F. Do not freeze. Protect from light. Do not shake.

Drug Interactions

Abatacept, anakinra

Do not coadminister with golimumab.

CYP substrates with a narrow therapeutic index (eg, cyclosporine, theophylline, warfarin)

Monitor the response and drug concentrations of CYP substrates with a narrow therapeutic index when starting or stopping golimumab.

Live vaccines

Do not coadminister live vaccines.

TNF antagonists

Risk of infection may be increased; do not coadminister.

Laboratory Test Interactions

None well documented.

Adverse Reactions

CNS

Dizziness (2%); paresthesia, pyrexia (1%).

EENT

Nasopharyngitis (6%); pharyngitis, rhinitis (1%).

Lab Tests

Increased ALT (4%); increased AST (3%).

Local

Injection-site reactions (6%); injection-site erythema (3%).

Respiratory

Upper respiratory tract infection (7%); bronchitis, sinusitis (2%).

Miscellaneous

Golimumab antibodies (4%); hypertension (3%); influenza (2%); oral herpes (1%).

Precautions

Warnings

Patients treated with golimumab are at increased risk for developing serious infections that may lead to hospitalization or death. These patients are frequently taking concomitant immunosuppressants (eg, corticosteroids, methotrexate). Infections include active tuberculosis (TB), invasive fungal infections, or bacterial, viral, or other infections caused by opportunistic pathogens. Discontinue treatment in patients who develop serious infection or sepsis.

Monitor

Closely monitor for development of signs or symptoms of infection during and after treatment, including possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy. Closely monitor patients who are carriers of hepatitis B virus for signs of active hepatitis B virus infection throughout therapy and for several months after completion of therapy. Closely monitor patients with CHF and discontinue treatment if new or worsening symptoms of CHF appear.

Pregnancy

Category B .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Elderly

No overall differences in safety or efficacy have been observed in patients 65 yr of age and older compared with younger subjects.

CHF

Worsening of CHF and new-onset CHF have been reported with TNF-blockers.

Demyelinating disorders

Use of TNF-blockers has been associated with new onset or exacerbation of CNS demyelinating disorders (eg, multiple sclerosis).

Hematologic events

Pancytopenia, leukopenia, neutropenia, aplastic anemia, and thrombocytopenia have been reported with TNF-blockers during postmarketing experience.

Hepatitis B reactivation

Reactivation of hepatitis B virus has been reported in patients who are chronic hepatitis B carriers.

Latex

Needle cover on the prefilled syringe and the prefilled syringe on the auto-injector contain natural rubber, a derivative of latex, which should not be handled by persons sensitive to latex.

Malignancies

Lymphomas have occurred.

Vaccinations

Patients may receive vaccinations, except for live vaccines.

Overdosage

Symptoms

There were no overdoses in clinical studies.

Patient Information

  • Instruct patients to notify their health care provider if they develop any symptoms of infection.
  • Advise patients sensitive to latex that the needle cover on the prefilled syringe and the prefilled auto-injector contain natural rubber, a derivative of latex.

Copyright © 2009 Wolters Kluwer Health.

  • Golimumab MedFacts Consumer Leaflet (Wolters Kluwer)
  • golimumab Subcutaneous Advanced Consumer (Micromedex) - Includes Dosage Information
  • Simponi Prescribing Information (FDA)
  • Simponi Consumer Overview

See Also...

Comment «Golimumab»